Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy 2025-05-23 16:16
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy 2025-04-29 14:00
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy 2024-10-17 14:30
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy 2024-04-24 15:00
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy 2024-02-23 15:00
1